Marshall Wace North America L.P. bought a new position in Natus Medical Incorporated (NASDAQ:BABY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 157,609 shares of the medical equipment provider’s stock, valued at approximately $5,832,000. Marshall Wace North America L.P. owned about 0.48% of Natus Medical as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Natus Medical by 137,510.8% in the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock worth $161,874,000 after buying an additional 4,121,198 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Natus Medical by 4.8% in the first quarter. Vanguard Group Inc. now owns 2,274,870 shares of the medical equipment provider’s stock worth $89,289,000 after buying an additional 105,008 shares during the last quarter. Columbia Wanger Asset Management LLC boosted its position in shares of Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock worth $79,686,000 after buying an additional 1,439,382 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after buying an additional 922,268 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Natus Medical by 2.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,401,566 shares of the medical equipment provider’s stock worth $55,010,000 after buying an additional 38,125 shares during the last quarter. 92.65% of the stock is owned by institutional investors and hedge funds.

Shares of Natus Medical Incorporated (BABY) opened at 32.80 on Tuesday. The firm has a market cap of $1.07 billion, a PE ratio of 56.85 and a beta of 0.93. The stock has a 50 day moving average price of $35.42 and a 200 day moving average price of $36.37. Natus Medical Incorporated has a 52 week low of $31.65 and a 52 week high of $44.39.

Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.01. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The firm had revenue of $122.20 million during the quarter, compared to the consensus estimate of $121.99 million. During the same period last year, the firm posted $0.39 EPS. The firm’s revenue for the quarter was up 27.3% on a year-over-year basis. Equities analysts expect that Natus Medical Incorporated will post $1.70 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/157609-shares-in-natus-medical-incorporated-baby-acquired-by-marshall-wace-north-america-l-p/1529173.html.

BABY has been the subject of a number of recent research reports. Zacks Investment Research cut Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. BidaskClub raised Natus Medical from a “sell” rating to a “hold” rating in a report on Saturday, July 1st. Finally, Benchmark Co. reaffirmed a “buy” rating and issued a $48.00 target price (down previously from $55.00) on shares of Natus Medical in a report on Monday, May 1st. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $45.00.

In other news, Director William M. Moore sold 3,000 shares of Natus Medical stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $34.10, for a total transaction of $102,300.00. Following the completion of the sale, the director now directly owns 30,410 shares in the company, valued at $1,036,981. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider James B. Hawkins purchased 4,000 shares of the stock in a transaction dated Thursday, June 15th. The shares were purchased at an average price of $33.98 per share, with a total value of $135,920.00. Following the completion of the acquisition, the insider now owns 578,023 shares of the company’s stock, valued at $19,641,221.54. The disclosure for this purchase can be found here. Company insiders own 5.50% of the company’s stock.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.